PRINCETON, N.J. Danish drug maker Novo Nordisk will remove 25 microgram doses of a treatment for atrophic vaginitis in menopausal women from the U.S. market to comply with the recommendations of medical professionals, Novo Nordisk said Thursday.

The company said Vagifem (estradiol) vaginal suppositories will only be available in the 10 microgram strength starting July 30. The Food and Drug Administration approved the drug in November 2009.

Medical societies such as the North American Menopause Society have recommended that the women should use the lowest effective dose of estrogen consistent with treatment goals, benefits and risks.